PHARMA MAR, S.A. «12345...» Page 5 out of 22 31/01/2024 19:05 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from January 1 to January 31, 2024. Ending of the Acquisition of Treasury Shares and resumption of the liquidity contract. Register number: 26379 30/01/2024 17:35 PHARMA MAR, S.A. On corporate governance The Company informs of changes in the chairmanship of the Appointments and Compensation and Sustainability Committee. Register number: 26362 08/01/2024 17:37 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from December 1 to December 31, 2023. Register number: 26121 18/12/2023 08:26 PHARMA MAR, S.A. On business and financial situation Sylentis, a subsidiary of Pharma Mar, announces that the FYDES study to evaluate the safety of tivanisiran in patients with dry eye disease has met its primary endpoint. Register number: 25836 12/12/2023 14:33 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in Hong Kong. Register number: 25763 05/12/2023 17:38 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from November 1 to November 30, 2023. Register number: 25709 04/12/2023 08:31 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner Luye Pharma Group Ltd has received approval for commercialization for Zepzelca® (lurbinectedina) in Macao. Register number: 25626 07/11/2023 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces that its partner Adium Pharma has received approval for commercialization for Zepzelca® (lurbinectedina) in Peru. Register number: 25260 06/11/2023 17:37 PHARMA MAR, S.A. Share buy-back , stabilisation and treasury stock programmes The Company reports on treasury share acquisitions in the period from October 1 to October 31, 2023 Register number: 25251 06/11/2023 08:26 PHARMA MAR, S.A. On business and financial situation The Company announces a US$10 million milestone payment from Janssen Products LP Register number: 25247 Page 5 out of 22 «12345...»
